Commentary: Takeda/Alnylam Best Alliance Deal Of 2008?
This article was originally published in PharmAsia News
Takeda Pharmaceuticals' May collaboration with U.S.-based Alnylam and its RNAi work was one of the best deals in that class of drugs in 2008. The move even topped Takeda's alliance with Amgen and acquisition of Millennium, both of the United States, earlier in the year. The Anylam alliance also could help the American company gain access to candidate drugs under development by other drug makers and even obtain a partner for its RNAi work elsewhere in Asia. All of that is in addition to the alliance's arrangement for Alnylam to share in marketing rights for up to four Takeda programs of Alnylam's choosing. It also allows Alnylam to finish the year with $500 million during a global financial crisis. (Click here for more
You may also be interested in...
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.